<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437982</url>
  </required_header>
  <id_info>
    <org_study_id>628</org_study_id>
    <nct_id>NCT01437982</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%</brief_title>
  <official_title>A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to identify any adverse events or adverse drug reactions
      through post-marketing surveillance under routine clinical practice
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to identify any adverse events or adverse drug reactions
      through post-marketing surveillance under routine clinical practice after marketing
      authorization of Lotemax ophthalmic suspension 0.5%
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>4 years</time_frame>
    <description>All adverse events that occurred from the first dose of the study drug regardless of causality to the study drug. Changes in all undesirable medical findings and all adverse events occurring with the use of the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seasonal Allergic Conjunctivitis</measure>
    <time_frame>4 years</time_frame>
    <description>Signs and symptoms of seasonal allergic conjunctivitis: The efficacy assessment will be evaluated according to the classification: improved, unchanged, worsened, impossible to assess.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Giant Papillary Conjunctivitis</measure>
    <time_frame>4 years</time_frame>
    <description>Signs and symptoms of giant papillary conjunctivitis: The results of the efficacy assessment will be evaluated according to the classification: improved, unchanged, worsened, impossible to assess.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative inflammation</measure>
    <time_frame>4 years</time_frame>
    <description>Treatment of post-operative inflammation following ocular surgery: The results of the final efficacy assessment will be evaluated according to the classification: improved, unchanged, worsened, impossible to assess.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Conjunctivitis, Seasonal Allergic</condition>
  <condition>Conjunctivitis, Giant Papillary</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ophthalmic Gel 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone Acetate 1% Oph Susp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ophthalmic suspension 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate</intervention_name>
    <description>Ocular administration of study drug. at least once within any indication of the label.</description>
    <arm_group_label>Loteprednol Etabonate</arm_group_label>
    <other_name>Lotemax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1% Oph Susp</intervention_name>
    <description>Ocular administration of study drug. at least once within any indication of the label.</description>
    <arm_group_label>Prednisolone Acetate 1% Oph Susp</arm_group_label>
    <other_name>Prednisolone Acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have been treated with the study drug at least once and completed safety
             follow-up.

          -  Subjects who have been treated with the study drug at least once and completed the
             clinical efficacy assessment.

        Exclusion Criteria:

          -  Subjects not treated with study drug at least once.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binu Alexander, MD</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Korea Ltd</name>
      <address>
        <city>Seoul</city>
        <zip>135-280</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post-operative inflammation</keyword>
  <keyword>conjunctivitis</keyword>
  <keyword>safety</keyword>
  <keyword>Seasonal allergic conjunctivitis</keyword>
  <keyword>Giant papillary conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

